Asian Pacific Journal of Cancer Prevention

  • 제15권13호
  • /
  • Pages.5137-5142
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Down-regulation of miRNA-452 is Associated with Adriamycin-resistance in Breast Cancer Cells

  • Hu, Qing (Department of General Surgery, Nanjing Medical University Affiliated Jiangsu Cancer Hospital) ;
  • Gong, Jian-Ping (Department of General Surgery, Nanjing Medical University Affiliated Jiangsu Cancer Hospital) ;
  • Li, Jian (Department of General Surgery, Nanjing Medical University Affiliated Jiangsu Cancer Hospital) ;
  • Zhong, Shan-Liang (Clinical Laboratory Center, Jiangsu Cancer Hospital) ;
  • Chen, Wei-Xian (Department of General Surgery, Nanjing Medical University Affiliated Jiangsu Cancer Hospital) ;
  • Zhang, Jun-Ying (Department of General Surgery, Nanjing Medical University Affiliated Jiangsu Cancer Hospital) ;
  • Ma, Teng-Fei (Clinical Laboratory Center, Jiangsu Cancer Hospital) ;
  • Ji, Hao (Department of General Surgery, Nanjing Medical University Affiliated Jiangsu Cancer Hospital) ;
  • Lv, Meng-Meng (Department of General Surgery, Nanjing Medical University Affiliated Jiangsu Cancer Hospital) ;
  • Zhao, Jian-Hua (Clinical Laboratory Center, Jiangsu Cancer Hospital) ;
  • Tang, Jin-Hai (Department of General Surgery, Nanjing Medical University Affiliated Jiangsu Cancer Hospital)
  • 발행 : 2014.07.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Adriamycin (ADR) is an important chemotherapeutic agent frequently used in treatment of breast cancer. However, resistance to ADR results in treatment failure in many patients. Recent studies have indicated that microRNAs (miRNAs) may play an important role in such drug-resistance. In the present study, microRNA-452 (miR-452) was found to be significantly down-regulated in adriamycin-resistant MCF-7 cells (MCF-7/ADR) compared with the parental MCF-7 cells by miRNA microarray and real-time quantitative PCR (RT-qPCR). MiR-452 mimics and inhibitors partially changed the adriamycin-resistance of breast cancer cells, as also confirmed by apoptosis assay. In exploring the potential mechanisms of miR-452 in the adriamycin-resistance of breast cancer cells, bioinformatics analysis, RT-qPCR and Western blotting showed that dysregulation of miR-452 played an important role in the acquired adriamycin-resistance of breast cancer, maybe at least in part via targeting insulin-like growth factor-1 receptor (IGF-1R).

키워드

참고문헌

  1. Anaya-Ruiz M, Cebada J, Delgado-Lopez G, et al (2013). miR-153 silencing induces apoptosis in the MDA-MB-231 breast cancer cell line. Asian Pac J Cancer Prev, 14, 2983-6. https://doi.org/10.7314/APJCP.2013.14.5.2983
  2. Anglicheau D, Muthukumar T, Suthanthiran M (2010). MicroRNAs: small RNAs with big effects. Transplantation, 90, 105-12.
  3. Barrett SV (2010). Breast cancer. J R Coll Physicians Edinb, 40, 335-8. https://doi.org/10.4997/JRCPE.2010.418
  4. Beech DJ, Parekh N, Pang Y (2001). Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncol Rep, 8, 325-9.
  5. Chen J, Tian W, Cai H, et al (2012). Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol, 29, 2527-34. https://doi.org/10.1007/s12032-011-0117-4
  6. Haenisch S, Cascorbi I (2012). miRNAs as mediators of drug resistance. Epigenomics, 4, 369-81. https://doi.org/10.2217/epi.12.39
  7. Howe EN, Cochrane DR, Richer JK (2011). Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res, 13, R45. https://doi.org/10.1186/bcr2867
  8. John B, Enright AJ, Aravin A, et al (2004). Human MicroRNA targets. PLoS Biol, 2, e363. https://doi.org/10.1371/journal.pbio.0020363
  9. Jurmeister S, Baumann M, Balwierz A, et al (2012). MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol, 32, 633-51. https://doi.org/10.1128/MCB.06212-11
  10. Kovalchuk O, Filkowski J, Meservy J, et al (2008). Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther, 7, 2152-9. https://doi.org/10.1158/1535-7163.MCT-08-0021
  11. Kutanzi KR, Yurchenko OV, Beland FA, et al (2011). MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics, 2, 171-85. https://doi.org/10.1007/s13148-011-0040-8
  12. Li JY, Zhang Y, Zhang WH, et al (2013a). Effects of differential distribution of microvessel density, possibly regulated by miR-374a, on breast cancer prognosis. Asian Pac J Cancer Prev, 14, 1715-20. https://doi.org/10.7314/APJCP.2013.14.3.1715
  13. Li JY, JiaS, Zhang WH, et al (2013b). Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes. Asian Pac J Cancer Prev, 14, 3197-203. https://doi.org/10.7314/APJCP.2013.14.5.3197
  14. Li XJ, Ji MH, Zhong SL, et al (2012). MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch Med Res, 43, 514-21. https://doi.org/10.1016/j.arcmed.2012.09.007
  15. Peruzzi F, Prisco M, Dews M, et al (1999). Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol, 19, 7203-15. https://doi.org/10.1128/MCB.19.10.7203
  16. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  17. Tian W, Chen J, He H, et al (2013). MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. Clin Transl Oncol, 15, 335-42. https://doi.org/10.1007/s12094-012-0929-5
  18. Tryndyak VP, Beland FA, Pogribny IP (2010). E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer, 126, 2575-83.
  19. Wang ZX, Lu BB, Wang H, et al (2011). MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res, 42, 281-90. https://doi.org/10.1016/j.arcmed.2011.06.008
  20. Xiong L, Kou F, Yang Y, et al (2007). A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop. J Cell Biol, 178, 995-1007. https://doi.org/10.1083/jcb.200703044
  21. Zeng X, Zhang H, Oh A, et al (2012). Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Res Treat, 133, 117-26. https://doi.org/10.1007/s10549-011-1713-x
  22. Zhong S, Li W, Chen Z, et al (2013). MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene, 531, 8-14. https://doi.org/10.1016/j.gene.2013.08.062

피인용 문헌

  1. miR-340 Reverses Cisplatin Resistance of Hepatocellular Carcinoma Cell Lines by Targeting Nrf2-dependent Antioxidant Pathway vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10439
  2. MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer vol.55, pp.5, 2016, https://doi.org/10.1002/mc.22320
  3. Expression and function of microRNA-497 in human osteosarcoma vol.14, pp.1, 2016, https://doi.org/10.3892/mmr.2016.5256
  4. Decreased microRNA-452 expression and its prognostic significance in human osteosarcoma vol.14, pp.1, 2016, https://doi.org/10.1186/s12957-016-0900-y
  5. How interacting pathways are regulated by miRNAs in breast cancer subtypes vol.17, pp.S12, 2016, https://doi.org/10.1186/s12859-016-1196-1
  6. Mechanisms of doxorubicin resistance in hepatocellular carcinoma vol.3, pp.1, 2016, https://doi.org/10.2217/hep.15.41
  7. Expression of microRNA-452 via adenoviral vector inhibits non-small cell lung cancer cells proliferation and metastasis vol.37, pp.6, 2016, https://doi.org/10.1007/s13277-015-4725-z
  8. Clinical value of miR-452-5p expression in lung adenocarcinoma: A retrospective quantitative real-time polymerase chain reaction study and verification based on The Cancer Genome Atlas and Gene Expression Omnibus databases vol.39, pp.5, 2017, https://doi.org/10.1177/1010428317705755
  9. Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A vol.14, pp.2, 2017, https://doi.org/10.3892/ol.2017.6426
  10. MicroRNA-184 inhibits cell proliferation and metastasis in human colorectal cancer by directly targeting IGF-1R vol.14, pp.3, 2017, https://doi.org/10.3892/ol.2017.6499
  11. MicroRNA-452 suppresses pancreatic cancer migration and invasion by directly targeting B-cell-specific Moloney murine leukemia virus insertion site 1 vol.14, pp.3, 2017, https://doi.org/10.3892/ol.2017.6566
  12. MicroRNA-379 acts as a tumor suppressor in non-small cell lung cancer by targeting the IGF-1R-mediated AKT and ERK pathways vol.38, pp.3, 2017, https://doi.org/10.3892/or.2017.5835
  13. MicroRNA-455 is downregulated in gastric cancer and inhibits cell proliferation, migration and invasion via targeting insulin-like growth factor 1 receptor vol.16, pp.3, 2017, https://doi.org/10.3892/mmr.2017.6979
  14. MicroRNA-592 targets IGF-1R to suppress cellular proliferation, migration and invasion in hepatocellular carcinoma vol.13, pp.5, 2017, https://doi.org/10.3892/ol.2017.5902
  15. N-peptide of vMIP-II reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer vol.51, pp.3, 2017, https://doi.org/10.3892/ijo.2017.4076
  16. A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance vol.25, pp.2, 2018, https://doi.org/10.1038/cdd.2017.176
  17. Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals vol.17, pp.1, 2018, https://doi.org/10.1186/s12943-018-0906-x
  18. Identification of cancer-related miRNA-lncRNA biomarkers using a basic miRNA-lncRNA network vol.13, pp.5, 2018, https://doi.org/10.1371/journal.pone.0196681
  19. The role and mechanisms of action of microRNAs in cancer drug resistance vol.11, pp.1, 2019, https://doi.org/10.1186/s13148-018-0587-8